← All trials
NCT06855108
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2025
- Primary completion
- Dec 31, 2029
- Completion date
- Jul 31, 2030
- First posted
- Mar 3, 2025
- Last posted
- Mar 3, 2025
- Enrollment
- 830
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Child Health and Human Development (NICHD)Lead sponsor
- Bill and Melinda Gates FoundationCollaborator
- University of KinshasaCollaborator
- University of Alabama, BirminghamCollaborator
- Lata Medical Research Foundation, Nagpur, IndiaCollaborator
- RTI InternationalCollaborator
- RTI InternationalOfficial
- Institute of Nutrition of Central America and PanamaCollaborator
- Columbia UniversityCollaborator
- University of North Carolina at Chapel HillOfficial
- International Center for Diarrheal Disease ResearchCollaborator
- Aga Khan UniversityCollaborator
- University of North Carolina at Chapel HillCollaborator
- University of Colorado, DenverCollaborator
- Thomas Jefferson UniversityCollaborator
- University of VirginiaCollaborator
- University Teaching Hospital, Lusaka, ZambiaCollaborator
- Jawaharlal Nehru Medical CollegeCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.